TempraMed Technologies Ltd, a leader in smart temperature-controlled medical devices, has signed an exclusive distribution agreement with Dolfin Saglik Ürünleri, one of Turkey’s most established healthcare and medical device companies. Under the agreement, Dolfin Saglik will distribute TempraMed’s VIVI line of temperature-stabilizing medication products across Turkey.

Founded in 2002, Dolfin Saglik works with major public and private hospitals, emergency services, educational institutions and regional health authorities. The company has built nationwide reach based on service reliability, innovation, and high-quality medical solutions.

Turkey represents a major growth opportunity for TempraMed due to its high diabetes burden. Nearly 10 million people in the country live with diabetes, with more than 1 million using insulin and many others relying on GLP-1 therapies. These patients use temperature-sensitive medications that can easily degrade when exposed to heat or cold. TempraMed’s VIVI products use patented smart insulation technology to maintain safe temperatures without external cooling, protecting medications such as insulin, biologics, EpiPens, fertility treatments and GLP-1 therapies.

Ron Nagar, CEO of TempraMed, said the partnership with Dolfin Saglik marks a major step in expanding into a large and fast-growing diabetes market. “Dolfin’s deep relationships with hospitals, emergency services and patient networks make them an ideal commercialization partner. This agreement supports our broader global strategy as we continue to expand our product line and scale both our B2B and direct-to-consumer businesses.”

Tolga Oruço?lu, General Manager of Dolfin Saglik, highlighted the need for reliable solutions in Turkey’s climate. “VIVI offers temperature protection unlike anything currently available. Patients need dependable protection for temperature-sensitive medications during daily use, travel and extreme weather. TempraMed’s products deliver validated safety and simplicity without the need for cooling or daily maintenance.”

The partnership supports TempraMed’s shift from primarily online direct-to-consumer sales toward broader adoption through pharmacies, distributors, insurers and institutional healthcare providers. The deal is expected to accelerate uptake among insulin-dependent and GLP-1-using patients, as well as hospitals, clinics, diabetes educators and national procurement bodies.

TempraMed holds more than eight global patents and continues to expand access to its maintenance-free technology, which prevents degradation and potency loss in temperature-sensitive injectable medications.

Dolfin Saglik brings a strong national distribution network and longstanding presence across hospitals, emergency services, clinics and consumer segments, offering significant potential for rapid market penetration of TempraMed’s VIVI products. This agreement is one of several European expansion partnerships currently underway as part of TempraMed’s strategic growth plan.